Can neoadjuvant chemotherapy change clinic pathological and survival parameters in HER-2 positive breast cancer patients?

被引：0
|
作者：
Mundim, F. [1 ]
Franco, A. [1 ]
Infante, K. [1 ]
Neto, J. [1 ]
Brentani, M. M. [1 ]
Facina, G. [1 ]
Waitzberg, A. [1 ]
机构：
[1] Univas Brazil, Pathol, Pouso Alegre, Brazil
来源：
VIRCHOWS ARCHIV | 2018年 / 473卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
E-PS-02-04
引用
收藏
页码：S209 / S209
页数：1
相关论文
共 50 条
  • [21] Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive Metastatic Breast Cancer
    Berghoff, Anna S.
    Bago-Horvath, Zsuzsanna
    Dubsky, Peter
    Rudas, Margaretha
    Pluschnig, Ursula
    Wiltschke, Christoph
    Gnant, Michael
    Steger, Guenther G.
    Zielinski, Christoph C.
    Bartsch, Rupert
    BREAST JOURNAL, 2013, 19 (02): : 149 - 155
  • [22] Factors influencing survival of 107 HER2 positive breast cancer patients treated with trastuzumab based neoadjuvant chemotherapy
    Favier, L.
    Guiu, S.
    Dunach, E.
    Assous, D.
    Bonnetain, F.
    Gligorov, J.
    Stockmeier, V.
    Vasseur, B.
    Fumoleau, P.
    Coudert, B.
    EJC SUPPLEMENTS, 2007, 5 (04): : 201 - 201
  • [23] Microtubule-associated protein tau is a marker of pathological complete response in Her-2/neu positive neoadjuvant treated breast cancer patients
    Rueckert, S.
    Wirtz, R.
    Lenhard, M.
    Hasmueller, S.
    Ditsch, N.
    Ruehl, I
    Kahlert, S.
    Bauerfeind, I
    Untch, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S89 - S90
  • [24] CLINICAL AND ECONOMIC ISSUES IN ADJUVANT CHEMOTHERAPY FOR HER-2 POSITIVE BREAST CANCER
    Martins, Sandro Jose
    Yamamoto, Crystina Aoki
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2008, 54 (06): : 494 - 499
  • [25] Microtubule-associated protein tau is a marker of pathological complete response in Her-2/neu positive neoadjuvant treated breast cancer patients
    Rueckert, S.
    Wirtz, R. M.
    Lenhard, M. S.
    Hasmueller, S.
    Ditsch, N.
    Ruehl, I.
    Kahlert, S.
    Bauerfeind, I.
    Fasching, P. A.
    Untch, M.
    EJC SUPPLEMENTS, 2008, 6 (07): : 191 - 192
  • [26] Treatment of HER-2 positive breast cancer
    Clavarezza, Matteo
    Venturini, Marco
    EJC SUPPLEMENTS, 2008, 6 (14): : 21 - 25
  • [27] Evolution and prognostic significance of HER-2 conversion from primary to residual disease in HER-2 negative patients with breast cancer after neoadjuvant chemotherapy
    Chen, Xi
    Ji, Lei
    Qian, Xiaoyan
    Xiao, Min
    Li, Qing
    Wang, Jiayu
    Fan, Ying
    Luo, Yang
    Lan, Bo
    Chen, Shanshan
    Ma, Fei
    Xu, Binghe
    Zhang, Pin
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (08):
  • [28] Immunotherapy for HER-2 positive breast cancer
    Yang, Tingting
    Kang, Lihua
    Li, Dan
    Song, Yanqiu
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] The Pathological Response of Her2+Breast Cancer with Neoadjuvant Chemotherapy and Radiation Therapy
    Chao, M.
    Baker, C.
    Jassal, S.
    Law, M.
    Bevington, E.
    Stoney, D.
    Zantuck, N.
    Chew, G.
    Loh, S. W.
    Hyett, A.
    Guerrieri, M.
    Ng, M.
    Cokelek, M.
    Neoh, D.
    Yong, C.
    Ho, H.
    Tacey, M.
    Joon, D. Lim
    Khor, R.
    Foroudi, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E17 - E17
  • [30] HER-2 positive inflammatory breast cancer: high pathological response rate with trastuzumab-based neoadjuvant therapy.
    Dawood, S.
    Gonzales-Angulo, A. M.
    Broglio, k
    Gong, Y.
    Resetkova, E.
    Yang, W. T.
    Barnett, C. M.
    Islam, R.
    Ueno, N. T.
    Hortobagyi, G. N.
    Cristofanilli, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S186 - S186
12345